




RealRate

PHARMACEUTICAL 2014

Arrowhead Pharmaceuticals INC
Rank 134 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Arrowhead Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arrowhead Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Arrowhead Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 13% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	28,844
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,725
Liabilities, Non-Current	2,870
Other Assets	4,973
Other Compr. Net Income	0
Other Expenses	12,685
Other Liabilities	0
Other Net Income	-7,114
Other Revenues	290
Property and Equipment	3,513
Research and Development	8,706
Selling, General and Administrative Expense	3,489

Output Variable	Value in 1000 USD
Assets	37,330
Liabilities	11,595
Expenses	24,880
Revenues	290
Stockholders Equity	25,735
Net Income	-31,703
Comprehensive Net Income	-31,703
BaseVar	40,604
ECR before LimitedLiability	100%
Economic Capital Ratio	230%